{"id":30112,"date":"2026-07-02T21:30:00","date_gmt":"2026-07-02T19:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=3a0ff0495219f7ec65a13d86bcbe36d2"},"modified":"2026-07-02T21:30:00","modified_gmt":"2026-07-02T19:30:00","slug":"maat-pharma-monthly-information-regarding-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=30112","title":{"rendered":"MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital"},"content":{"rendered":"

\nArticle 223-16 of the General Regulations of the Financial Markets Authority\n(AMF - Autorit\u00e9 des March\u00e9s Financiers)<\/i><\/p>

LYON, France--(BUSINESS WIRE)--$MAAT<\/a>--Regulatory News:<\/p><\/a><\/a>

\nMaaT Pharma<\/a> (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM <\/sup>(MET) dedicated to enhancing survival for patients with cancer through immune modulation, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorit\u00e9 des March\u00e9s Financiers<\/i> (AMF)) on June 30, 2026.<\/p>

\nListing place<\/b>: Euronext Paris\nISIN code:<\/b> FR0012634822\nWebsite<\/b>: www.maatpharma.com<\/a><\/p>\n\n\n\n\n

\nDate<\/p><\/td>

\nTotal number of shares\ncomprising the share capital<\/p><\/td>

\nTotal number of\ntheoretical voting rights (1)<\/sup><\/p><\/td>

\nTotal number of\neffective voting rights (2)<\/sup><\/p><\/td><\/tr>\n

\n06\/30\/26<\/p><\/td>

\n18,863,543<\/p><\/td>

\n18,863,543<\/p><\/td>

\n18,817,925<\/p><\/td><\/tr>\n

\n(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.<\/i><\/p><\/td><\/tr>\n

\n(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.<\/i><\/p><\/td><\/tr>\n<\/table>

\nAbout MaaT Pharma\nMaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.<\/p> Contacts<\/b>

\nMaaT Pharma \u2013 Investor Relations\nEric Soyer\nChief Financial Officer\n+33 4 28 29 14 00\ninvest@maat-pharma.com<\/a>\nMaaT Pharma \u2013 Media Relations\nPauline Richaud\nHead of Communications\n+33 6 14 06 45 92\nmedia@maat-pharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Article 223-16 of the General Regulations of the Financial Markets Authority
\n(AMF – Autorit\u00e9 des March\u00e9s Financiers)LYON, France–(BUSINESS WIRE)–$MAAT–Regulatory News:
\nMaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology com…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-30112","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30112"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30112\/revisions"}],"predecessor-version":[{"id":30113,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/30112\/revisions\/30113"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}